Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Jan 2020 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 18 Feb 2015 Planned End Date changed from 1 May 2018 to 1 May 2016, according to ClnicalTrials.gov record.